Neurocrine Biosciences (NBIX) Amortization of Deferred Charges (2017 - 2023)
Neurocrine Biosciences' (NBIX) quarterly Amortization of Deferred Charges came in at $100000.0 in Q4 2023, down 50.0% on a YoY basis from $200000.0 in Q4 2022, and down 50.0% quarter-over-quarter from $200000.0 in Q3 2023.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Amortization of Deferred Charges (2017 - 2023) Analysis & Trends
Neurocrine Biosciences (NBIX) has reported Amortization of Deferred Charges for 7 consecutive years, with $100000.0 the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Amortization of Deferred Charges fell 50.0% year-over-year to $100000.0; the trailing twelve-month figure through Dec 2023 stood at $700000.0 (down 41.67% YoY), and the FY2023 full-year result was $700000.0, down 41.67% from the prior year.
- Amortization of Deferred Charges fell to $100000.0 in Q4 2023 per NBIX's latest filing, from $200000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $400000.0 in Q2 2019 and bottomed at $100000.0 in Q4 2023.
- Historically, Amortization of Deferred Charges has averaged $290000.0 across 5 years, with a median of $300000.0 in 2019.
- The sharpest annual moves came in 2022 and 2023: Amortization of Deferred Charges surged 33.33% in 2022, then slumped 50.0% in 2023.
- Over 5 years, Amortization of Deferred Charges stood at $400000.0 in 2019, then changed by 0.0% to $400000.0 in 2020, then slipped by 25.0% to $300000.0 in 2021, then slumped by 33.33% to $200000.0 in 2022, then plunged by 50.0% to $100000.0 in 2023.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $100000.0, $200000.0, and $200000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 200,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Dec 31, 2022 | 200,000.00 |
| Sep 30, 2022 | 200,000.00 |
| Jun 30, 2022 | 400,000.00 |
| Mar 31, 2022 | 400,000.00 |
| Dec 31, 2021 | 300,000.00 |
| Sep 30, 2021 | 200,000.00 |
| Jun 30, 2021 | 300,000.00 |
| Mar 31, 2021 | 300,000.00 |
| Dec 31, 2020 | 400,000.00 |
| Sep 30, 2020 | 300,000.00 |
| Jun 30, 2020 | 400,000.00 |
| Mar 31, 2020 | 300,000.00 |
| Dec 31, 2019 | 400,000.00 |
| Sep 30, 2019 | 300,000.00 |
| Jun 30, 2019 | 400,000.00 |
| Mar 31, 2019 | 300,000.00 |